Prostate cancer — all decisions

The Board granted earlier effective dates for service connection and related benefits, including prostate cancer, erectile dysfunction, special monthly compensation, and DEA benefits, all effective May 10, 2022.

The Board granted service connection for coronary artery disease, hypertension, and prostate cancer based on the Veteran's exposure to herbicide agents during his service near the Korean Demilitarized Zone.

The Board is remanding the issues of service connection for bladder cancer, prostate cancer, and diabetes mellitus for readjudication.

The Board denied service connection for prostate cancer and remanded the claims for hypertension, ED, and SMC based on loss of use.

The Board denied the claims for an earlier effective date and a compensable rating for bladder cancer and prostate cancer, as service connection was granted under the PACT Act on August 10, 2022.

The Board remands the claims for service connection for prostate cancer, diabetes mellitus Type II, and erectile dysfunction due to pre-decisional duty to assist errors.

The Board granted service connection for PTSD, denied service connection for a left hip disability and prostate cancer, and denied a compensable rating for bilateral hearing loss.

The veteran withdrew the appeal for service connection for prostate cancer before a decision was made.

The Board denied service connection for hearing loss and tinnitus, while remanding the claims for coronary artery disease (CAD), prostate cancer, obstructive sleep apnea, cataracts, and thyroid removal due to a duty to assist error.

The Board denied the veteran's claims for increased ratings and service connection, as the evidence did not support higher evaluations or establish service connection.

The Board granted service connection for prostate cancer, diabetes mellitus with hypoglycemia, erectile dysfunction secondary to prostate cancer, and urinary incontinence secondary to prostate cancer. The claims for a bilateral eye disability, bilateral foot disability, joint pain (also claimed as arthritis), respiratory disorder, lung disability, chronic gastritis, and liver disability were remanded.

The Board granted service connection for urinary retention (also noted as incontinence) and found that the reduction of the disability evaluation for prostate cancer, s/p with residual bladder/urinary dysfunction, from 20 percent to noncompensable was improper.

The Board remands the claims for service connection for varicose veins, phimosis, and a left eye injury to obtain additional medical opinions.

The Board denied the Veteran's claim for special monthly compensation based on housebound status after December 31, 2023, as there was no single service-connected disability rated at 100 percent.

The appeal for special monthly pension based on the need for aid and attendance was dismissed, while a 100 percent rating was granted for prostate cancer prior to August 20, 2024.

The Board remands the claims for service connection for erectile dysfunction and prostate cancer, status-post prostatectomy, to obtain additional medical evidence regarding their etiology, particularly in relation to the Veteran's confirmed exposure to contaminated water at Camp Lejeune.

The Board denied the Veteran's claims for service connection for diabetes mellitus, type II and prostate cancer due to a lack of evidence supporting direct causation or presumptive exposure.

The Board denied service connection for a benign frontotemporal brain tumor and prostate cancer, finding that the evidence did not support a causal relationship between these conditions and the Veteran's military service.

The Board denied the Veteran's claim for an effective date prior to December 20, 2022, for a 100 percent evaluation of prostate cancer (status post radical prostatectomy).

The Board denied service connection for prostate cancer as the evidence did not support a link between the Veteran's condition and his active duty service.